



OTC Pink Basic Disclosure Guidelines

Quarter Ending December 31, 2018

(Read FORM 10-Q filed with the US SEC on February 14, 2019 for the Six Month Ending December 31, 2018).

- 1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

Current Name: Predictive Technology Group, Inc. –

07/16/2015 Former Name: Global Enterprises Group, Inc.-

03/12/2014

- 2) Address of the issuer's principal

executive offices Company Headquarters

Address 1: 2735 East Parleys Way, Suite

205 Address 2: Salt Lake City, UT 84109

Phone: 1-888-407-9761

Email: info@predictivetechnologygroup.com

Website(s):

www.predictivertechnologygroup.com

IR Contact

Address 1: LHA Investor Relations

Address 2: 2121 Avenue of the Stars, Suite 2970

Address 3: Los Angeles, CA 90067

Phone: 310-691-7100

Email: jcain@lhai.com

Website(s): www.lhai.com

- 3) Security

Information Trading

Symbol: PRED

Exact title and class of securities outstanding:

CUSIP: 74039H102

Par or Stated Value: \$0.001 Common

Total shares authorized: 900,000,000 as of: February 13, 2019

Total shares outstanding: 248,846,403 as of: February 13, 2019

Additional class of securities (if necessary): Trading Symbol: N/A

Exact title and class of securities outstanding: 10,000,000 shares preferred par value \$0.001 CUSIP: none

Par or Stated Value: \$ 0.001
Total shares authorized: 10,000,000 as of: February 13, 2019
Total shares outstanding: -0- as of: February 13, 2019

Transfer Agent

Name: Transfer Online, Inc.

Address 1: 512 SE Salmon Street

Address 2: Portland, OR 97214

Address 3: www.transferonline.com

Phone: Phone #503-227-2950

Is the Transfer Agent registered under the Exchange Act?* Yes: No:

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security: NONE

Describe any trading suspension orders issued by the SEC in the past 12 months. NONE

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

During the past two years the Company issued (or is obligated to issue) the following shares:
(Read FORM 10-Q filed with the US SEC on February 14, 2019 for the Six Month Ending December 31, 2018).

- 1) Warrants exercisable for 2,400,000 shares of common stock were issued to Flagshipsailsrx, LLC ("Flagship"), an accredited investor, in March 2018 (the "2018 Warrants"). Flagship manages the Company's sales team, distributors and marketing efforts. In February 2017, the Company agreed to issue the 2018 Warrants when annualized sales, computed on a monthly basis, reached \$20,000,000. This milestone was achieved in March 2018. In February 2017, the Company issued to Flagship warrants exercisable for 4,800,000 shares of common stock was part of the original consideration to retain Flagship to manage the Company's sales, distribution and marketing efforts. In August 2017, the Company issued to Flagship warrants exercisable for 4,800,000 shares of common stock as a bonus that was agreed when annualized sales, computed on a monthly basis, reached \$10,000,000. All of the above referenced warrants are exercisable at \$0.50 per share and expire between June 2022 and August 2022. The issuance of the warrants was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. There are no additional milestones that will require the issuance of additional securities to Flagship under existing arrangements.
- 2) In August 2016, 5,740,760 shares of restricted common stock in connection with the acquisition of certain debt obligations of a strategic partner. 5,822,206 shares of restricted common stock in connection with the acquisition of a strategic partner. These acquisitions were exempt from registration requirements pursuant to Section 4(a)(2) of the Securities Act of 1933. The certificates evidencing the shares contained a legend; (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act. These shares were issued to residents of the United States.

- 3) In August 2016, 550,000 shares of restricted common stock in connection with the acquisition of intellectual property from accredited investors. These acquisitions were exempt from registration requirements pursuant to Section 4(a)(2) of the Securities Act of 1933. The certificates evidencing the shares contained a legend; (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act. These shares were issued to residents of the United States.
- 4) From August 2016 to October 2017, 675,000 shares of restricted common stock in connection with services performed on behalf of the Company. This transaction was exempt from registration requirements pursuant to Section 4(a)(2) of the Securities Act of 1933. The certificates evidencing the shares contained a legend; (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.
- 5) From July 2016 to the present, 15,948,520 shares of common stock together with warrants exercisable for 15,948,520 shares of common stock were sold to accredited investors at a price of \$0.50 per unit. The warrants are exercisable through August 1, 2021. This transaction was exempt from registration requirements pursuant to Section 4(a)(2) of the Securities Act of 1933. The certificates evidencing the shares contained a legend; (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.
- 6) From October 2017 to the present, options have been granted to employees that are exercisable for up to 4,938,500 shares of common stock. The options are exercisable at prices of between \$0.50 and \$1.00 per share. The issuance of the warrants was exempt from registration requirements pursuant to Section 4(a)(2) of the Securities Act of 1933.
- 7) Warrants exercisable for 14,000,000 shares of common stock and 1,000,000 shares of common stock were issued to Juneau Bioscience, LLC in December 2017 to amend the license agreements to reduce the royalty rate under and expand the scope of the licenses to include the entire field of endometriosis and pelvic pain. The above referenced warrants are exercisable at \$0.80 per share and expire on September 1, 2022. The issuance of the warrants was exempt from registration requirements pursuant to Section 4(a)(2) of the Securities Act of 1933.
- 8) In May 2018, 727,917 shares of restricted common stock were issued as payment for services in the development of protocols for the use of HCT/P's in specified medical procedures.
- 9) In August 2018, 50,000 shares of restricted common stock were issued to a supplier to secure raw materials for the HCT/P segment of business.
- 10) In August 2018, the company entered into an agreement to issue warrants exercisable for 16,500,000 shares of common stock were issued to acquire certain assets of Taueret Laboratories, LLC. The warrants are exercisable at \$.92 per share and expire on September 1, 2022.
- 11) In August 2018, 15,500,000 shares of restricted stock were issued to accredited investors in a connection with Securities Purchase Agreement to acquire Inception DX, to be used as a CLIA laboratory in addition to cash, protocols, equipment and other assets.
- 12) In October 2018, warrants exercisable for 300,000 shares of common stock were issued to an accredited consultant for consulting services relating to the Company's existing and proposed laboratory facilities. The above referenced warrants are exercisable at \$0.94 per share and expire on September 1, 2022. The issuance of the warrants was exempt from registration requirements pursuant to Section 4(a)(2) of the Securities Act of 1933.

5) Financial Statements

(Read FORM 10-Q filed with the US SEC on February 14, 2019 for the Six Month Ending December 31, 2018).

Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualification for the OTC Pink Current Information tier. For the initial disclosure statement (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.

- A. Balance sheet;
- B. Statement of income;
- C. Statement of cash flows;
- D. Financial notes; and
- E. Audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with US GAAP by persons with sufficient financial skills.

You may either (i) attach/append the financial statements to this disclosure statement or (ii) post such financial statements through the OTC Disclosure & News Service as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial reports separately as described in part (ii) above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to otcq.com in the field below.

Information contained in a Financial Report is considered current until the due date for the subsequent Financial Report. To remain in the OTC Pink Current Information tier, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of its fiscal quarter-end date.

6) Describe the Issuer's Business, Products and Services

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

- A. a description of the issuer's business operations;

(Read FORM 10-Q filed with the US SEC on February 14, 2019 for the Six Month Ending December 31, 2018).

Predictive Technology Group, Inc., a publicly traded entity with stock symbol, PRED which traded on the OTC, looks to improve lives by identifying, developing, acquiring and commercializing medical apparatuses and treatments that address human medical needs.

Predictive Technology Group, Inc., through its wholly owned subsidiaries, Predictive Therapeutics ("PRx") and Predictive Biotech, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics.

PRx has developed and/or acquired a number of proprietary technologies that open a window into the origin of human disease and the role that genes and their related proteins play in the disease's onset and progression.

PRx uses this information as the cornerstone in the development of new diagnostics that assess a person's risk of disease and therapeutic products designed to effectively prevent and/or treat the disease.

PRx's utilization of molecular diagnostics focuses on the analysis of genes and their mutations to assess a patient's inherited risk for developing a particular disease and its progression (predictive healthcare). Additionally, PRx believes that advances in the emerging field of molecular diagnostics will improve the ability to determine which patients are

subject to a greater risk of developing disease, and who therefore would benefit from preventive therapies. Molecular diagnostic products may also guide a patient's healthcare to ensure the patient receives the most appropriate treatment at the most appropriate time (i.e., most effective).

PRx is well positioned with short and long-term assets in its pipeline to be a leader in the future of preventative, personalized and precision healthcare. Current trends in medicine lie in the creation of new classes of drugs that treat the underlying cause, not just the symptoms, of disease and may be useful in disease prevention. By understanding the genetic basis of disease and by working with strategic partners, PRx believes that it will be able to develop drugs and treatment protocols that are more effective, resulting in better patient outcomes at significantly lower costs.

PRx's development expertise is uniquely enhanced by its strategic development collaborations. Some of those development assets are included below:

- 600,000 DNA samples in library as a result of a birth defect or serious maternity issue
- HIPAA compliant
- Collected from most genetically diverse population in U.S.
- Believed to be largest DNA library in world related to women's health
- Corresponding proprietary genealogy database developed from over 50,000 public sources
- Gen DB – Proprietary genealogy database used to accelerate genetic discoveries

The first expected diagnostic PRED, through its subsidiary Predictive Therapeutics, expects to commercialize is a genetic diagnostic for endometriosis to the fertility market. PRx then will focus development resources on its proprietary genetic based diagnostics for scoliosis and degenerative disc disease.

NHP-07 – First pharmaceutical/therapeutic candidate to be developed by PRx. Management believes NHP-07 with EndoRisk® as a companion diagnostic/prognostic is the only treatment protocol that may suppress/prevent development of endometriosis and its debilitating symptoms.

Genetic diagnostics do not require approval by the FDA in order to go to market if the tests are Laboratory Developed Tests ("LDTs"), which are regulated under the Clinical Laboratory Improvement Amendments ("CLIA"). The American Clinical Laboratory Association ("ACLA") filed a citizen petition on June 4, 2013 challenging the FDA's authority to regulate LDTs as medical devices under the federal Food, Drug, and Cosmetic Act (FDCA). The ACLA stated, "CLIA allows laboratories the flexibility to develop and validate LDTs quickly to respond to public health needs." The ACLA also wrote, "Laboratories are able to update LDTs regularly as medicine advances, so that patients have access to the most advanced testing." LDTs are laboratory services, not products, and are not distributed, nor delivered or placed into market, noted the petition. "They are proprietary procedures for performing a diagnostic test using reagents and laboratory equipment, essentially know-how."

Predictive Biotech develops and commercializes minimally manipulated allograft products from umbilical cord and placental tissue.

- Human Cell and Tissue Products include:
 - CoreCyte™ is a minimally manipulated human tissue allograft suspension derived from the Wharton's Jelly of the umbilical cord. CoreCyte™ is processed to preserve the biological and structural integrity of Wharton's jelly for homologous use.
 - PolyCyte™ is a minimally manipulated human tissue allograft suspension derived from the Wharton's Jelly of the umbilical cord. PolyCyte™ is processed to preserve the molecular profiles of cytokines, growth factors and proteins in Wharton's jelly for homologous use.
 - AmnioCyte Plus™ is a minimally manipulated human tissue allograft suspension derived from the extracellular matrix of the amniotic membrane. AmnioCyte Plus™ is processed to preserve the cellular scaffolding proteins and cytokines in amniotic membrane for homologous use.

- AmnioCyte™ is a minimally manipulated human tissue allograft derived from amniotic fluid. AmnioCyte™ is processed to preserve the molecular profiles of cytokines, growth factors and proteins in amniotic fluid for homologous use.

Proven and Experienced Team: PRED has an experienced team that has completed similar product ventures from conception to commercialization through internal sales and marketing and/or major strategic partnerships. The key executives have a track record of successfully developing and marketing high volume products in the healthcare field. As a result, PRED will be able to benefit from and leverage valuable relationships with industry leaders. Discussions have already commenced with significant companies that have major women's health franchises.

Predictive Technology Group, Inc. through its acquisitions of Predictive Therapeutics, LLC, Predictive Biotech, Inc. and LifeCode Genetics, Inc. has a number of patents and licenses agreements.

Predictive Technology Group, Inc. as of June 30, 2018, PRED owns 49% (approx.) of Juneau Biosciences, LLC which came about through the aforementioned acquisition of LifeCode Genetics, Inc, conversion of Convertible Debt and a Subscription agreement with Juneau.

B. Date and State (or Jurisdiction) of Incorporation:

August 25, 2005, State of NEVADA

C. the issuer's primary and secondary SIC Codes:

Primary S.I.C- 8731; Secondary SIC- 2835

D. the issuer's fiscal year end date: **June 30**

E. Principal products or services, and their markets:

(Read FORM 10-Q filed with the US SEC on February 14, 2019 for the Six Month Ending December 31, 2018).

Predictive Technology Group, Inc., a publicly traded entity with stock symbol, PRED which traded on the OTC, looks to improve lives by identifying, developing, acquiring and commercializing medical apparatuses and treatments that address human medical needs.

Predictive Technology Group, Inc., through its wholly owned subsidiaries, Predictive Therapeutics ("PRx") and Predictive Biotech, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics.

PRx has developed and/or acquired a number of proprietary technologies that open a window into the origin of human disease and the role that genes and their related proteins play in the disease's onset and progression.

PRx uses this information as the cornerstone in the development of new diagnostics that assess a person's risk of disease and therapeutic products designed to effectively prevent and/or treat the disease.

PRx's utilization of molecular diagnostics focuses on the analysis of genes and their mutations to assess a patient's inherited risk for developing a particular disease and its progression (predictive healthcare). Additionally, PRx believes that advances in the emerging field of molecular diagnostics will improve the ability to determine which patients are subject to a greater risk of developing disease and who therefore would benefit from preventive therapies. Molecular diagnostic products may also guide a patient's healthcare to ensure the patient receives the most appropriate treatment at the most appropriate time (i.e., most effective).

PRx is well positioned with short and long-term assets in its pipeline to be a leader in the future of preventative, personalized and precision healthcare. Current trends in medicine lie in the creation of new classes of drugs that treat the underlying cause, not just the symptoms, of disease and may be useful in disease prevention. By understanding the

genetic basis of disease and by working with strategic partners, PRx believes that it will be able to develop drugs and treatment protocols that are more effective, resulting in better patient outcomes at significantly lower costs.

Genetic diagnostics do not require approval by the FDA in order to go to market if the tests are Laboratory Developed Tests (“LDTs”), which are regulated under the Clinical Laboratory Improvement Amendments (“CLIA”). The American Clinical Laboratory Association (“ACLA”) filed a citizen petition on June 4, 2013 challenging the FDA’s authority to regulate LDTs as medical devices under the federal Food, Drug, and Cosmetic Act (FDCA). The ACLA stated, “CLIA allows laboratories the flexibility to develop and validate LDTs quickly to respond to public health needs.” The ACLA also wrote, “Laboratories are able to update LDTs regularly as medicine advances, so that patients have access to the most advanced testing.” LDTs are laboratory services, not products, and are not distributed, nor delivered or placed into market, noted the petition. “They are proprietary procedures for performing a diagnostic test using reagents and laboratory equipment, essentially know-how.”

NHP-07 – First pharmaceutical/therapeutic candidate to be developed by PRx. Management believes NHP-07 with EndoRisk® as a companion diagnostic/prognostic is the only treatment protocol that can suppress/prevent development of endometriosis and its debilitating symptoms.

- Approximately 7.5 million women suffer from endometriosis in the United States with only 2.5 million women currently diagnosed
- Approximately 70 million women worldwide are symptomatic of endometriosis
- Greater than \$1Billion annual US market
- Tremendous need for new more effective/lower side-effect therapeutics to meet this unmet demand
- Suppresses the symptoms of endometriosis in women diagnosed with endometriosis
- Prevents/suppresses the development of the disease
- Combination of two or more existing FDA-approved compounds, whose safety have been established over decades
- Coupled with EndoRisk® as a companion diagnostic, NHP-07 may be given prior to development of endometriosis or becoming symptomatic to prevent the disease altogether
- Patent issued October 2015 for combination of progesterone and NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
- Patent issued October 2015 for combination of progesterone and cannabinoids

(Read FORM 10-Q filed with the US SEC on February 14, 2019 for the Six Month Ending December 31, 2018).

Predictive Biotech develops and commercializes minimally manipulated allograft products from umbilical cord and placental tissue.

- Human Cell and Tissue Products include:
 - CoreCyte™ is a minimally manipulated human tissue allograft suspension derived from the Wharton’s Jelly of the umbilical cord. CoreCyte™ is processed to preserve the biological and structural integrity of Wharton’s jelly for homologous use.
 - PolyCyte™ is a minimally manipulated human tissue allograft suspension derived from the Wharton’s Jelly of the umbilical cord. PolyCyte™ is processed to preserve the molecular profiles of cytokines, growth factors and proteins in Wharton’s jelly for homologous use.
 - AmnioCyte Plus™ is a minimally manipulated human tissue allograft suspension derived from the

extracellular matrix of the amniotic membrane. AmnioCyte Plus™ is processed to preserve the cellular scaffolding proteins and cytokines in amniotic membrane for homologous use.

- AmnioCyte™ is a minimally manipulated human tissue allograft derived from amniotic fluid. AmnioCyte™ is processed to preserve the molecular profiles of cytokines, growth factors and proteins in amniotic fluid for homologous use.

Proven and Experienced Team: PRED has an experienced team that has completed similar product ventures from conception to commercialization through internal sales and marketing and/or major strategic partnerships. The key executives have a track record of successfully developing and marketing high volume products in the healthcare field. As a result, PRED will be able to benefit from and leverage valuable relationships with industry leaders. Discussions have already commenced with significant companies that have major women's health franchises.

(Read FORM 10-Q filed with the US SEC on February 14, 2019 for the Six Month Ending December 31, 2018).

7) Describe the Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

Corporate Office-Predictive Therapeutics: 2735 East Parleys Way, Suite 205, Salt Lake City, UT 84109, \$6,228 per month, on a month to month lease, includes administrative offices, lab space, lab benches and lab equipment.

Corporate Lab Facility: 615 Arapeen Drive, Suite 300, Salt Lake City, UT 84108, \$12,051 per month, on a two year lease, includes administrative offices, lab space, lab benches and lab equipment.

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

- A. **Names of Officers, Directors, and Control Persons.** In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Mr. John Sorrentino is Chairman

Mr. Bradley Robinson is President / Director

Mr. Michael Dey is Director

Mr. Merle Ferguson is Director

Mr. Simon Brewer is CFO

Mr. Paul Evans is COO

(Read FORM 10-Q filed with the US SEC on February 14, 2019 for the Six Month Ending December 31, 2019).

- B. **Legal/Disciplinary History.** Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

- C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

Bradley C. Robinson, CEO - 42,492,482 common shares

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel- Intellectual Property

Name: Vern Norviel

Firm: Wilson Sonsini Goodrich &

Rosati Address 1: 650 Page Mill Road

Address 2: Palo Alto, CA 94304-1050

Phone: 650-493-9300

Email: vnorniel@wsgr.com

Legal Counsel-Securities

Name: Richard W. Jones

Firm: Jones & Haley, P.C.

Address: 750 Hammond Drive, Building 12, Suite 100

Atlanta, GA. 30328

Telephone: 770-804-0500

http://www.corplaw.net

Accountant or Auditor Name:

Ben Borgers, CPA, CVA

Firm: BF Borgers CPA, PC

Address 1: 5400 West Cedar Avenue

Address 2: Lakewood, CO 80226

Phone: 303-953-1454
Email: ben@bjbcpa.us

Investor Relations Consultant

Name: Keith Lippert
Firm: LHA Investor Relations
Address 1: LHA Investor Relations
Address 2: 2121 Avenue of the Stars, Suite 2970
Address 3: Los Angeles, CA 90067
Phone: 310-691-7100
Email: jcain@lhai.com
Website(s): www.lhai.com

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Merle Ferguson certify that:

1. I have reviewed this Quarter-end report, December 31, 2018, disclosure document of Predictive Technology Group, Inc.:
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

February 14, 2019

Director

(Read FORM 10-Q filed with the US SEC on February 14, 2019 for the Six Month Ending December 31, 2019).